Further, using flow cytometry, the proportions of Tregs (CD4+CD25+Foxp3+) cells in the peripheral blood of healthy volunteers, newly diagnosed DLBCL patients, rituximab chemotherapy-sensitive patients, and rituximab-resistant patients were measured. The gene discussed is CD4; the disease is diffuse large B-cell lymphoma.